Evidence map›Paper›PMID 35269919›Full record

ArticleInternational journal of molecular sciences2022

Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses.

Ruxu Zhai, Erika L Varner, Ajay Rao, Sunil Karhadkar, Antonio Di Carlo, Nathaniel W Snyder, Priscila Y Sato

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. GRK2 and Mitochondrial Dynamics in Cardiovascular Health and Disease.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Molecular Mechanisms Underlying Chronic and Degenerative Diseases.International journal of molecular sciences · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ruxu ZhaiDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.ORCID 0000-0002-7058-4019
Erika L VarnerCenter for Metabolic Disease Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.
Ajay RaoCenter for Metabolic Disease Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.
Sunil KarhadkarDepartment of Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.ORCID 0000-0001-7943-0203
Antonio Di CarloDepartment of Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.ORCID 0000-0002-0516-5483
Nathaniel W SnyderCenter for Metabolic Disease Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.
Priscila Y SatoDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.ORCID 0000-0003-0512-7011
Temple University · USDrexel University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G-protein coupled receptor (GPCR) kinase 2 (GRK2) is upregulated in heart failure (HF) patients and mouse models of cardiac disease. GRK2 is a regulator of β-adrenergic receptors (βARs), a GPCR involved in ionotropic and chronotropic responses. We and others have recently reported GRK2 to be localized in the mitochondria, although its function in the mitochondria and/or metabolism remain not clearly defined. We hypothesized that upregulation of GRK2 reduced mitochondrial respiratory function and responses to βAR activation. Utilizing isolated mouse primary adult cardiomyocytes (ACMs), we investigated the role of glucose, palmitate, ketone bodies, and BCAAs in mediating cell survival. Our results showed that myocyte upregulation of GRK2 promotes palmitate-induced cell death. Isotopologue labeling and mass spectrometry showed that the upregulation of GRK2 reduces β-hydroxybutyryl CoA generation. Next, using isoproterenol (ISO), a non-selective βAR-agonist, we determined mitochondrial function in mouse and human primary ACMs. Upregulation of GRK2 impaired ISO-mediated mitochondrial functional responses, which we propose is important for metabolic adaptations in pathological conditions. Increased cardiac levels of GRK2 reduced fatty acid-specific catabolic pathways and impaired ISO-stimulated mitochondrial function. Our data support the notion that GRK2 participates in bioenergetic remodeling and may be an important avenue for the development of novel pharmacological strategies in HF.

Indexed as

Heart FailureReceptors, Adrenergic, betaAnimalsFatty AcidsG-Protein-Coupled Receptor Kinase 2HumansIsoproterenolMiceMitochondriaMyocytes, CardiacPalmitatesFatty AcidsG-Protein-Coupled Receptor Kinase 2GRK2 protein, mouseIsoproterenolPalmitatesReceptors, Adrenergic, betabeta-adrenergic receptorscardiomyocytesGRK2metabolismmitochondria

Identifiers

PMID35269919
PMCPMC8911442
OpenAlexW4214821302

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.